BlackThorn Therapeutics is a clinical-stage biopharmaceutical company. Founded by Alex Tkachenko in 2013, BlackThorn Therapeutics is backed by investors that include Alexandria Real Estate Equities, Alexandria Venture Investments, ARCH Venture Partners, GV, and Johnson & Johnson Innovation and is headquartered in South San Francisco.